세계의 선천성 부신 과형성증 시장 보고서(2025년)

Congenital Adrenal Hyperplasia Global Market Report 2025

US $ 4,490 ￦ 6,344,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,170,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,996,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

선천성 부신 과형성증 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.1%로 성장할 전망이며, 6억 6,000만 달러로 성장이 예측됩니다. 이 예측 기간 동안의 성장은 맞춤형 의료에 대한 수요 증가, 유전성 질환의 발생률 증가, 선천성 부신 과형성증 치료에 관한 조사 증가, 헬스케어 투자 증가, 증상 관리에 있어서 원격 의료 이용 확대 등에 기인하고 있습니다. 주요 동향으로는 헬스케어 인프라 발전, 분자진단학 진보, 효소 보충 요법 개발, 장시간 작용형 코르티코스테로이드 제제 개발, 유전자 스크리닝의 개선 등을 들 수 있습니다.

유전자 치료에 대한 수요가 높아지면 향후 수년간 선천성 부신 과형성증 시장의 성장을 견인할 것으로 예측됩니다. 유전자 치료는 질병의 치료나 예방을 위해 개인의 유전자를 수정 및 조작하는 의료 기술입니다. 유전자 치료에 대한 수요가 높아지는 것은 유전자 연구 및 바이오 기술의 진보로 유전성 질환, 암, 기타 만성 질환에 대한 보다 정확하고 집중적인 치료가 가능해졌기 때문입니다. 부신호르몬 생성에 영향을 미치는 유전자 변이에 기인한 선천성 부신 과형성증(CAH)은 유전자 치료의 중요한 분야로 근본적인 결함을 수정하고 정상적인 호르몬 기능을 회복시키는 표적 유전자 개입의 기회를 제공하고 있습니다. 예를 들어 2024년 4월 미국을 거점으로 하는 전문가 회원 조직인 미국유전자세포치료학회(ASGCT)는 희귀질환을 대상으로 개발 중인 유전자 치료제 1,023건 중 상위 10건 중 8건이 종양 질환을 대상으로 하고 있다고 보고했습니다. 게다가 2024년 2분기에는 유전자 치료 임상시험이 25% 증가해 새롭게 76개 시험이 시작됐습니다. 이러한 유전자 치료에 대한 수요 증대가 선천성 부신 과형성증 시장 확대에 기여하고 있습니다.

선천성 부신 과형성증 시장의 주요 기업은 코르티솔 생산을 조절하고 부신 안드로겐 과잉을 억제하는 CRF1 수용체 길항제와 같은 혁신적인 치료법의 개발에 주력하고 있습니다. CRF1 수용체 길항제는 코르티코트로핀 방출 인자 1(CRF1) 수용체를 차단하는 약물로 신체의 스트레스 반응을 조절하고 CAH와 같은 상태에서 부신 안드로겐 과잉 생산을 억제하는 데 도움이 됩니다. 예를 들어, 2024년 12월 미국 바이오 의약품 회사 뉴로클라인 바이오사이언시스는 70년 만에 선천성 부신 과형성증의 새로운 치료제인 클레네스(클리네커 폰트)의 FDA 승인을 받았습니다. 이 내복제는 코르티코트로핀 방출 인자 1형 수용체의 선택적 길항제로서 작용하여 과도한 부신피질자극호르몬(ACTH)과 부신 안드로겐의 조절을 돕는 동시에 글루코코르티코이드의 저용량 투여를 가능하게 합니다. 승인은 CAHtalyst 3단계 시험의 데이터를 기반으로 하며, 안드로겐 수준을 낮추는 유의한 효과가 나타났습니다. Crenessity는 곧 출시 될 예정이며 CAH 관리의 큰 진보입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 선천성 부신 과형성증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 선천성 부신 과형성증 시장 : 성장률 분석
• 세계의 선천성 부신 과형성증 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 선천성 부신 과형성증 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 선천성 부신 과형성증 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 선천성 부신 과형성증 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 클래식 선천성 부신 과형성증
• 비클래식 선천성 부신 과형성증
• 세계의 선천성 부신 과형성증 시장 : 치료 및 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 진단
• 치료
• 세계의 선천성 부신 과형성증 시장 : 최종 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 전문 클리닉
• 외래수술센터(ASC)
• 연구기관
• 세계의 선천성 부신 과형성증 시장 : 선천성 부신 과형성증 병형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 소금 낭비 클래식 선천성 부신 과형성증
• 단순 바이러스화 클래식 선천성 부신 과형성증
• 세계의 선천성 부신 과형성증 시장 : 비전형적 선천성 부신 과형성증 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 만발성 비전형성 선천성 부신 과형성증
• 마일드한 비클래식 선천성 부신 과형성증

제7장 지역별 및 국가별 분석

• 세계의 선천성 부신 과형성증 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 선천성 부신 과형성증 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

• 선천성 부신 과형성증 시장 : 경쟁 구도
• 선천성 부신 과형성증 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
  • Thermo Fisher Scientific Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Takeda Pharmaceutical Company Limited 개요, 제품 및 서비스, 전략 및 재무 분석
  • Eli Lilly and Company 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Eton Pharmaceuticals Inc
• Teva Pharmaceutical Industries
• Macleods Pharmaceuticals
• H. Lundbeck A/S
• Neurocrine Biosciences Inc.
• BridgeBio Pharma Inc
• Regenxbio Inc.
• Millendo Therapeutics Inc.
• Applied Therapeutics, Inc.
• OMass Therapeutics Limited
• ViennaLab Diagnostics GmbH
• EffRx Pharmaceuticals SA
• Adrenas Therapeutics Inc
• HBM Alpha Therapeutics
• Spruce Biosciences Inc.

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 선천성 부신 과형성증 시장(2029년) : 새로운 기회를 제공하는 국가
• 선천성 부신 과형성증 시장(2029년) : 새로운 기회를 제공하는 부문
• 선천성 부신 과형성증 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

Congenital adrenal hyperplasia (CAH) is a group of inherited disorders that impact adrenal gland function due to enzyme deficiencies, primarily 21-hydroxylase. Management involves hormone replacement therapy to regulate cortisol and aldosterone levels, suppress excess androgen production, and address symptoms such as electrolyte imbalances and abnormal physical development.

The main types of CAH are classic and non-classic congenital adrenal hyperplasia. Classic CAH is a genetic disorder mainly caused by 21-hydroxylase deficiency, resulting in cortisol deficiency, excess androgen production, and potential aldosterone loss. Diagnosis and treatment take place across various healthcare settings, including hospitals, specialty clinics, ambulatory surgical centers, and research institutes.

The congenital adrenal hyperplasia market research report is one of a series of new reports from The Business Research Company that provides congenital adrenal hyperplasia market statistics, including the congenital adrenal hyperplasia industry global market size, regional shares, competitors with the congenital adrenal hyperplasia market share, detailed congenital adrenal hyperplasia market segments, market trends, and opportunities, and any further data you may need to thrive in the congenital adrenal hyperplasia industry. This congenital adrenal hyperplasia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The congenital adrenal hyperplasia market size has grown strongly in recent years. It will grow from $0.47 billion in 2024 to $0.50 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historic period can be credited to the rising prevalence of congenital adrenal hyperplasia, increased adoption of corticosteroid therapies, growing healthcare expenditure, a heightened focus on pediatric care, and expanding government initiatives and reimbursement policies.

The congenital adrenal hyperplasia market size is expected to see strong growth in the next few years. It will grow to $0.66 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be credited to the rising demand for personalized medicine, an increasing incidence of genetic disorders, growing research on congenital adrenal hyperplasia treatments, higher healthcare investments, and the expanding use of telemedicine in managing the condition. Key trends include advancements in healthcare infrastructure, progress in molecular diagnostics, the development of enzyme replacement therapies, the creation of long-acting corticosteroid formulations, and improvements in genetic screening.

The increasing demand for gene therapy is expected to drive the growth of the congenital adrenal hyperplasia market in the coming years. Gene therapy is a medical technique that involves modifying or manipulating an individual's genes to treat or prevent disease. The rising demand for gene therapy is fueled by advancements in genetic research and biotechnology, enabling more precise and targeted treatments for genetic disorders, cancers, and other chronic diseases. Congenital adrenal hyperplasia (CAH), which results from genetic mutations affecting adrenal hormone production, is a key area for gene therapy, offering opportunities for targeted genetic interventions to correct underlying defects and restore normal hormone function. For example, in April 2024, the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, reported that out of 1,023 gene therapies in development for rare diseases, eight of the top 10 targeted oncological conditions. Additionally, the second quarter of 2024 saw a 25% increase in gene therapy trials, with 76 new studies initiated. This growing demand for gene therapy is contributing to the expansion of the congenital adrenal hyperplasia market.

Leading companies in the congenital adrenal hyperplasia market are focusing on developing innovative treatments such as CRF1 receptor antagonists to regulate cortisol production and reduce adrenal androgen excess. CRF1 receptor antagonists are drugs that block the corticotropin-releasing factor 1 (CRF1) receptor, helping to regulate the body's stress response and control excessive adrenal androgen production in conditions such as CAH. For instance, in December 2024, Neurocrine Biosciences, Inc., a US-based biopharmaceutical company, received FDA approval for crenessity (crinecerfont), the first new treatment for congenital adrenal hyperplasia in 70 years. This oral medication functions as a selective antagonist of corticotropin-releasing factor type 1 receptors, helping to regulate excess adrenocorticotropic hormone (ACTH) and adrenal androgens while allowing for lower glucocorticoid doses. Approval was based on data from the CAHtalyst Phase 3 studies, which demonstrated significant efficacy in reducing androgen levels. Crenessity is expected to be available soon, representing a major advancement in CAH management.

In November 2022, Neurocrine Biosciences, Inc. expanded its portfolio by acquiring Diurnal Group Limited for an undisclosed amount. This acquisition aims to strengthen Neurocrine's presence in hormone therapeutics, accelerate the development of Diurnal's products, and enhance its market position in the UK for chronic endocrine diseases. Diurnal Group Limited, a UK-based biotech company, specializes in developing and commercializing hormone therapeutics for the treatment of chronic endocrine disorders, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism.

Major players in the congenital adrenal hyperplasia market are Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Eton Pharmaceuticals Inc, Teva Pharmaceutical Industries, Macleods Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences Inc., BridgeBio Pharma Inc, Regenxbio Inc., Millendo Therapeutics Inc., Applied Therapeutics, Inc., OMass Therapeutics Limited, ViennaLab Diagnostics GmbH, EffRx Pharmaceuticals SA, Adrenas Therapeutics Inc, HBM Alpha Therapeutics, Spruce Biosciences Inc., and Crinetics Pharmaceuticals Inc.

North America was the largest region in the congenital adrenal hyperplasia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in congenital adrenal hyperplasia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the congenital adrenal hyperplasia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The congenital adrenal hyperplasia market consists of revenues earned by entities by providing services such as telemedicine and remote monitoring, diagnostic testing services, hormone replacement therapy (HRT) services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital adrenal hyperplasia market also includes sales of glucocorticoids, mineralocorticoids, and adrenal androgens. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Congenital Adrenal Hyperplasia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on congenital adrenal hyperplasia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for congenital adrenal hyperplasia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The congenital adrenal hyperplasia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Classic Congenital Adrenal Hyperplasia; Non-Classic Congenital Adrenal Hyperplasia
• 2) By Treatment And Diagnosis: Diagnosis; Treatment
• 3) By End-Use: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Research Institutes
• Subsegments:
• 1) By Classic Congenital Adrenal Hyperplasia: Salt-Wasting Classic Congenital Adrenal Hyperplasia; Simple Virilizing Classic Congenital Adrenal Hyperplasia
• 2) By Non-Classic Congenital Adrenal Hyperplasia: Late-Onset Non-Classic Congenital Adrenal Hyperplasia; Mild Non-Classic Congenital Adrenal Hyperplasia
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Thermo Fisher Scientific Inc.; Takeda Pharmaceutical Company Limited; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Congenital Adrenal Hyperplasia Market Characteristics

3. Congenital Adrenal Hyperplasia Market Trends And Strategies

4. Congenital Adrenal Hyperplasia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Congenital Adrenal Hyperplasia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Congenital Adrenal Hyperplasia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Congenital Adrenal Hyperplasia Market Growth Rate Analysis
• 5.4. Global Congenital Adrenal Hyperplasia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Congenital Adrenal Hyperplasia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Congenital Adrenal Hyperplasia Total Addressable Market (TAM)

6. Congenital Adrenal Hyperplasia Market Segmentation

• 6.1. Global Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic Congenital Adrenal Hyperplasia
• Non-Classic Congenital Adrenal Hyperplasia
• 6.2. Global Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnosis
• Treatment
• 6.3. Global Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Research Institutes
• 6.4. Global Congenital Adrenal Hyperplasia Market, Sub-Segmentation Of Classic Congenital Adrenal Hyperplasia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Salt-Wasting Classic Congenital Adrenal Hyperplasia
• Simple Virilizing Classic Congenital Adrenal Hyperplasia
• 6.5. Global Congenital Adrenal Hyperplasia Market, Sub-Segmentation Of Non-Classic Congenital Adrenal Hyperplasia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Late-Onset Non-Classic Congenital Adrenal Hyperplasia
• Mild Non-Classic Congenital Adrenal Hyperplasia

7. Congenital Adrenal Hyperplasia Market Regional And Country Analysis

• 7.1. Global Congenital Adrenal Hyperplasia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Congenital Adrenal Hyperplasia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Congenital Adrenal Hyperplasia Market

• 8.1. Asia-Pacific Congenital Adrenal Hyperplasia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Congenital Adrenal Hyperplasia Market

• 9.1. China Congenital Adrenal Hyperplasia Market Overview
• 9.2. China Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Congenital Adrenal Hyperplasia Market

• 10.1. India Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Congenital Adrenal Hyperplasia Market

• 11.1. Japan Congenital Adrenal Hyperplasia Market Overview
• 11.2. Japan Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Congenital Adrenal Hyperplasia Market

• 12.1. Australia Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Congenital Adrenal Hyperplasia Market

• 13.1. Indonesia Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Congenital Adrenal Hyperplasia Market

• 14.1. South Korea Congenital Adrenal Hyperplasia Market Overview
• 14.2. South Korea Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Congenital Adrenal Hyperplasia Market

• 15.1. Western Europe Congenital Adrenal Hyperplasia Market Overview
• 15.2. Western Europe Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Congenital Adrenal Hyperplasia Market

• 16.1. UK Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Congenital Adrenal Hyperplasia Market

• 17.1. Germany Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Congenital Adrenal Hyperplasia Market

• 18.1. France Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Congenital Adrenal Hyperplasia Market

• 19.1. Italy Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Congenital Adrenal Hyperplasia Market

• 20.1. Spain Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Congenital Adrenal Hyperplasia Market

• 21.1. Eastern Europe Congenital Adrenal Hyperplasia Market Overview
• 21.2. Eastern Europe Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Congenital Adrenal Hyperplasia Market

• 22.1. Russia Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Congenital Adrenal Hyperplasia Market

• 23.1. North America Congenital Adrenal Hyperplasia Market Overview
• 23.2. North America Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Congenital Adrenal Hyperplasia Market

• 24.1. USA Congenital Adrenal Hyperplasia Market Overview
• 24.2. USA Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Congenital Adrenal Hyperplasia Market

• 25.1. Canada Congenital Adrenal Hyperplasia Market Overview
• 25.2. Canada Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Congenital Adrenal Hyperplasia Market

• 26.1. South America Congenital Adrenal Hyperplasia Market Overview
• 26.2. South America Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Congenital Adrenal Hyperplasia Market

• 27.1. Brazil Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Congenital Adrenal Hyperplasia Market

• 28.1. Middle East Congenital Adrenal Hyperplasia Market Overview
• 28.2. Middle East Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Congenital Adrenal Hyperplasia Market

• 29.1. Africa Congenital Adrenal Hyperplasia Market Overview
• 29.2. Africa Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Congenital Adrenal Hyperplasia Market Competitive Landscape And Company Profiles

• 30.1. Congenital Adrenal Hyperplasia Market Competitive Landscape
• 30.2. Congenital Adrenal Hyperplasia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Congenital Adrenal Hyperplasia Market Other Major And Innovative Companies

• 31.1. Eton Pharmaceuticals Inc
• 31.2. Teva Pharmaceutical Industries
• 31.3. Macleods Pharmaceuticals
• 31.4. H. Lundbeck A/S
• 31.5. Neurocrine Biosciences Inc.
• 31.6. BridgeBio Pharma Inc
• 31.7. Regenxbio Inc.
• 31.8. Millendo Therapeutics Inc.
• 31.9. Applied Therapeutics, Inc.
• 31.10. OMass Therapeutics Limited
• 31.11. ViennaLab Diagnostics GmbH
• 31.12. EffRx Pharmaceuticals SA
• 31.13. Adrenas Therapeutics Inc
• 31.14. HBM Alpha Therapeutics
• 31.15. Spruce Biosciences Inc.

32. Global Congenital Adrenal Hyperplasia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Congenital Adrenal Hyperplasia Market

34. Recent Developments In The Congenital Adrenal Hyperplasia Market

35. Congenital Adrenal Hyperplasia Market High Potential Countries, Segments and Strategies

• 35.1 Congenital Adrenal Hyperplasia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Congenital Adrenal Hyperplasia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Congenital Adrenal Hyperplasia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료